Drugs / Mesenchymal Stem Cells (MSCs)
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05578508 | Apr 2022 → Feb 2024 | Crohn disease, pouchitis, ulcerative colitis | The Cleveland Clinic | Withdrawn | No outcome recorded |
| Phase 1 | NCT04073472 | Jun 2021 → Jun 2022 | Crohn disease, anal fistula | The Cleveland Clinic | Withdrawn | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05284604 | Jan 2023 | — | VA Office of Research and Development | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02472002 | Jan 2014 → Jan 2018 | coronary artery disorder | Assistance Publique - Hôpitaux de Paris | Suspended | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01687777 Comparator | May 2010 → Jun 2013 | — | Hospital San Carlos, Madrid | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mesenchymal stem cells (MSCs) | “Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow” NCT02472002 ↗ |
| Known as | MSCs | “Mesenchymal Stem Cells (MSCs)” NCT01687777 ↗ |
| Modality | Cell therapy | “The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin” NCT02472002 ↗ |
| Route | Other | “direct injection” NCT04073472 ↗ |